clinicaltrials.gov
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days RSS akışı
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days için en son güncellemeleri olur olmaz al.
En yeni içerikler
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days içeriklerini kullandığınız okuma uygulamasına ekleyin
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days takipçileri bunları da takip ediyor
-
Chugai Pharmaceutical: News Releases chugai-pharm.co.jp
-
Bristol Myers Squibb Press Releases news.bms.com
-
Regeneron Pharmaceuticals Inc. News Releases investor.regeneron.com
-
What's new ema.europa.eu
Sorular
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days için RSS akışı URL'si nedir?
Akış adresi: https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=&lup_d=14&sel_rss=mod14&term=mezagitamab+%28TAK+079%29&recrs=abdf&type=Intr&phase=0124&fund=2&count=10000. Bunu herhangi bir RSS okuyucuya yapıştırın veya Feeder'da okumak için Şimdi takip et'e tıklayın.
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days ne sıklıkta gönderi yayınlıyor?
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days şu sıklıkta gönderi yayınlıyor: haftada bir kereden az. Son gönderi 12 gün önce yayınlandı.
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days RSS akışı çalışıyor mu?
Evet. Feeder akışı yaklaşık 1 saat önce kontrol etti ve akış normal yanıt verdi.
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days Feeder'da nasıl takip edilir?
Şimdi takip et'e tıklayın ve henüz hesabınız yoksa kaydolun. Feeder'ın ücretsiz planı web, iPhone ve Android'de 200'e kadar akışı kapsar. Kredi kartı gerekmez.
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days akışını Feeder'da takip edin
Feeder'ın ücretsiz planı web, iPhone ve Android'de 200'e kadar akışı kapsar. Kredi kartı gerekmez.